Oct. 23, 2020 12:00 UTC
OneSpan Wins CyberSecurity Breakthrough Award for Mobile Security Solution of the Year
OneSpan Wins CyberSecurity Breakthrough Award for Mobile Security Solution of the Year Oct. 23, 2020 12:00 UTC OneSpan Wins CyberSecurity Breakthrough Award for Mobile Security Solution of the Year International awards program recognizes company’s Mobile Security Suite for making mobile banking convenient and secure CHICAGO--(BUSINESS WIRE)-- OneSpan™ (NASDAQ: OSPN), the global leader in securing remote banking transactions, today announced that its Mobile Security Suite has been awarded “Overall Mobile Security Solution of the Year” from CyberSecurity Breakthrough, a leading independent market intelligence organization that recognizes the top companies, technologies and pro
Oct. 23, 2020 11:00 UTC
Cleveland-Cliffs Inc. Reports Third-Quarter 2020 Results
Cleveland-Cliffs Inc. Reports Third-Quarter 2020 Results Oct. 23, 2020 11:00 UTC Cleveland-Cliffs Inc. Reports Third-Quarter 2020 Results Third-quarter net income of $2 million Third-quarter adjusted EBITDA1 of $126 million Third-quarter cash from operations of $246 million CLEVELAND--(BUSINESS WIRE)-- Cleveland-Cliffs Inc. (NYSE: CLF) today reported third-quarter results for the period ended September 30, 2020. The Company reported total revenues of $1.6 billion, compared to the prior year's third-quarter consolidated revenues of $556 million. The Company recorded net income of $2 million during the third quarter of 2020. The loss of $0.02 per diluted share attributable to
Oct. 23, 2020 13:00 UTC
iHeartMedia to Acquire Voxnest
iHeartMedia to Acquire Voxnest Oct. 23, 2020 13:00 UTC iHeartMedia to Acquire Voxnest Voxnest Provides Leadership Role for iHeartMedia as the Consolidated Marketplace of Podcasting Adds Key Elements to iHeartMedia’s Podcast Technology Infrastructure and Platform, Including an Advanced Podcast Analytics Platform, Enterprise Publishing Tools, Programmatic Integration and Targeted Ad-Serving Capability Expands iHeartMedia’s Position as America’s #1 Commercial Podcast Publisher NEW YORK--(BUSINESS WIRE)-- iHeartMedia, the No. 1 audio company in America and the No. 1 commercial podcast publisher globally, today announced it has entered into an agreement to acquire Voxne
Oct. 23, 2020 15:00 UTC
INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Las Vegas Sands Corp. (LVS) Investors
INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Las Vegas Sands Corp. (LVS) Investors Oct. 23, 2020 15:00 UTC INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Las Vegas Sands Corp. (LVS) Investors BENSALEM, Pa.--(BUSINESS WIRE)-- Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Las Vegas Sands Corp. (“Las Vegas Sands ” or the “Company”) (NYSE: LVS) securities between February 27, 2016 and September 15, 2020, inclusive (the “Class Period”). Las Vegas Sands investors have until Dece
Oct. 23, 2020 16:30 UTC
The Law Offices of Frank R. Cruz Continues Its Investigation of Ra Medical Systems, Inc. (RMED) on Behalf of Investors
The Law Offices of Frank R. Cruz Continues Its Investigation of Ra Medical Systems, Inc. (RMED) on Behalf of Investors Oct. 23, 2020 16:30 UTC The Law Offices of Frank R. Cruz Continues Its Investigation of Ra Medical Systems, Inc. (RMED) on Behalf of Investors LOS ANGELES--(BUSINESS WIRE)-- The Law Offices of Frank R. Cruz continues its investigation of potential claims against the board of directors of Ra Medical Systems, Inc. (“Ra Medical” or the “Company”) (NYSE: RMED) concerning whether the board breached its fiduciary duties to shareholders. If you are a shareholder, click here to participate. Follow us for updates on Twitter: twitter.com/FRC_LAW. If you still ho
Oct. 23, 2020 12:00 UTC
PhaseBio Provides Pemziviptadil (PB1046) Program Update
PhaseBio Provides Pemziviptadil (PB1046) Program Update Oct. 23, 2020 12:00 UTC PhaseBio Provides Pemziviptadil (PB1046) Program Update VANGARD trial discontinued due to evolving COVID-19 treatment landscape, recent feedback from FDA regarding regulatory and development path, and interim analysis of trial data Enrollment expected to resume for ongoing Phase 2b trial of pemziviptadil in pulmonary arterial hypertension (PAH) MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)-- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced that,

Execution time: 0.3493 seconds
Layout: desktop